Carlo DeAngelis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1009610/publications.pdf

Version: 2024-02-01

176 papers 3,980 citations

147801 31 h-index 54 g-index

178 all docs

178 docs citations

178 times ranked 5132 citing authors

#	Article	IF	CITATIONS
1	Prophylaxis and Management of Acute Radiation-Induced Skin Reactions: A Systematic Review of the Literature. Current Oncology, 2010, 17, 94-112.	2.2	276
2	Role for Dual Individualization with Cefmenoxime. American Journal of Medicine, 1984, 77, 43-50.	1.5	181
3	Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncology, The, 2015, 16, 1463-1472.	10.7	142
4	Quality of life (QOL) and symptom burden (SB) in patients with breast cancer. Supportive Care in Cancer, 2017, 25, 409-419.	2.2	134
5	Prevalence of pain in patients with breast cancer post-treatment: A systematic review. Breast, 2018, 42, 113-127.	2.2	112
6	Continuous Narcotic Infusion with Patient-Controlled Analgesia for Chronic Cancer Pain in Outpatients. Annals of Internal Medicine, 1988, 108, 554.	3.9	109
7	A selective review of medical cannabis in cancer pain management. Annals of Palliative Medicine, 2017, 6, S215-S222.	1.2	107
8	ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Supportive Care in Cancer, 2019, 27, 87-95.	2.2	103
9	Cut points for mild, moderate, and severe pain among cancer and non-cancer patients: a literature review. Annals of Palliative Medicine, 2015, 4, 176-83.	1.2	96
10	Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Supportive Care in Cancer, 2014, 22, 1685-1697.	2.2	74
11	Effect of Radiotherapy on Painful Bone Metastases. JAMA Oncology, 2017, 3, 953.	7.1	73
12	Dexamethasone for the Prophylaxis of Radiation-induced Pain Flare after Palliative Radiotherapy for Symptomatic Bone Metastases: a Phase II Study. Clinical Oncology, 2009, 21, 329-335.	1.4	72
13	Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Supportive Care in Cancer, 2016, 24, 2381-2392.	2.2	72
14	Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer, 2010, 116, 742-748.	4.1	69
15	Radiation-induced Skin Toxicity in Breast Cancer Patients: A Systematic Review of Randomized Trials. Clinical Breast Cancer, 2018, 18, e825-e840.	2.4	66
16	Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology, 1992, 102, 1680-1685.	1.3	64
17	Inter-rater reliability in performance status assessment among health care professionals: a systematic review. Annals of Palliative Medicine, 2016, 5, 83-92.	1.2	64
18	Health System Costs for Stage-Specific Breast Cancer: A Population-Based Approach. Current Oncology, 2014, 21, 281-293.	2.2	57

#	Article	IF	CITATIONS
19	Retrospective Assessment of Cancer Pain Management in an Outpatient Palliative Radiotherapy Clinic Using the Pain Management Index. Journal of Pain and Symptom Management, 2010, 39, 259-267.	1.2	50
20	Efficacy of single fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review and meta-analysis. Annals of Palliative Medicine, 2017, 6, 125-142.	1.2	49
21	Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecologic Oncology, 1992, 47, 102-109.	1.4	46
22	Prophylaxis of Radiation-Induced Nausea and Vomiting Using 5-Hydroxytryptamine-3 Serotonin Receptor Antagonists: A Systematic Review of Randomized Trials. International Journal of Radiation Oncology Biology Physics, 2012, 82, 408-417.	0.8	46
23	Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review. Supportive Care in Cancer, 2016, 24, 3661-3668.	2.2	45
24	Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Supportive Care in Cancer, 2016, 24, 1001-1008.	2.2	45
25	Enteral and parenteral nutrition in cancer patients: a systematic review and meta-analysis. Annals of Palliative Medicine, 2016, 5, 30-41.	1.2	45
26	Consensus Recommendations for the Management of Constipation in Patients with Advanced, Progressive Illness. Journal of Pain and Symptom Management, 2010, 40, 761-773.	1.2	43
27	Does the Time of Radiotherapy Affect Treatment Outcomes? A Review of the Literature. Clinical Oncology, 2017, 29, 231-238.	1.4	42
28	Incidence of pain flare in radiation treatment of bone metastases: A literature review. Journal of Bone Oncology, 2014, 3, 84-89.	2.4	40
29	A systematic review and meta-analysis of clinician-reported versus patient-reported outcomes of radiation dermatitis. Breast, 2020, 50, 125-134.	2.2	39
30	Elderly Patients With Painful Bone Metastases Should be Offered Palliative Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1500-1506.	0.8	34
31	Quality of life and symptom burden in patients with metastatic breast cancer. Supportive Care in Cancer, 2016, 24, 4035-4043.	2.2	33
32	Inadequate pain management in cancer patients attending an outpatient palliative radiotherapy clinic. Supportive Care in Cancer, 2016, 24, 887-892.	2.2	33
33	Degradation kinetics of imipenem in normal saline and in human serum. Antimicrobial Agents and Chemotherapy, 1986, 29, 936-937.	3.2	32
34	National Dementia Strategies: What Should Canada Learn?. Canadian Geriatrics Journal, 2018, 21, 173-209.	1.2	32
35	The impact of psychosocial intervention on survival in cancer: a meta-analysis. Annals of Palliative Medicine, 2016, 5, 93-106.	1.2	30
36	Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis Against Febrile Neutropenia in Lymphoma Patients. Journal of the National Cancer Institute, 2013, 105, 1078-1085.	6.3	29

3

#	Article	IF	Citations
37	Quality of life and symptom burden in patients with breast cancer treated with mastectomy and lumpectomy. Supportive Care in Cancer, 2016, 24, 2191-2199.	2.2	29
38	Effects of circadian rhythms and treatment times on the response of radiotherapy for painful bone metastases. Annals of Palliative Medicine, 2017, 6, 14-25.	1.2	29
39	Symptom clusters in patients with breast cancer receiving radiation therapy. European Journal of Oncology Nursing, 2019, 42, 14-20.	2.1	29
40	Taxane-induced arthralgia and myalgia: A literature review. Journal of Oncology Pharmacy Practice, 2017, 23, 56-67.	0.9	28
41	Efficacy of multiple fraction conventional radiation therapy for painful uncomplicated bone metastases: A systematic review. Radiotherapy and Oncology, 2017, 122, 323-331.	0.6	28
42	Integration of patient-reported outcomes (PROs) for personalized symptom management in "real-world―oncology practices: a population-based cohort comparison study of impact on healthcare utilization. Supportive Care in Cancer, 2020, 28, 4933-4942.	2.2	28
43	International Patterns of Practice in the Management of Radiation Therapy-induced Nausea and Vomiting. International Journal of Radiation Oncology Biology Physics, 2012, 84, e49-e60.	0.8	27
44	A prospective study of gastrointestinal radiation therapy-induced nausea and vomiting. Supportive Care in Cancer, 2014, 22, 1493-1507.	2.2	27
45	Pain assessment tools for older adults with dementia in long-term care facilities: a systematic review. Neurodegenerative Disease Management, 2016, 6, 525-538.	2.2	27
46	A review of patterns of practice and clinical guidelines in the palliative radiation treatment of uncomplicated bone metastases. Radiotherapy and Oncology, 2017, 124, 38-44.	0.6	27
47	Do patients with brain metastases selected for whole brain radiotherapy have worse baseline quality of life as compared to those for radiosurgery or neurosurgery (with or without whole brain) Tj ETQq1 1 0.78431	.4 rgBT/Ov	verl ø øk 10 Tf
48	A Multicenter Assessment of the Adequacy of Cancer Pain Treatment Using the Pain Management Index. Journal of Palliative Medicine, 2010, 13, 589-593.	1.1	25
49	Side Effects Related to Systemic Cancer Treatment: Are We Changing the Promethean Experience with Molecularly Targeted Therapies?. Current Oncology, 2008, 15, 198-199.	2.2	24
50	The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases. Supportive Care in Cancer, 2014, 22, 1765-1771.	2.2	23
51	Opioid Prescribing Among Cancer and Non-cancer Patients: Time Trend Analysis in the Elderly Using Administrative Data. Journal of Pain and Symptom Management, 2017, 54, 484-492.e1.	1.2	23
52	Radiotherapy-induced nausea and vomiting. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 685-692.	1.4	22
53	Prophylaxis of radiotherapy-induced nausea and vomiting in the palliative treatment of bone metastases. Supportive Care in Cancer, 2012, 20, 1673-1678.	2.2	22
54	Comparison of the EORTC QLQ-BN20 and the FACT-Br quality of life questionnaires for patients with primary brain cancers: a literature review. Supportive Care in Cancer, 2014, 22, 2593-2598.	2.2	22

#	Article	IF	CITATIONS
55	Modulating the endocannabinoid pathway as treatment for peripheral neuropathic pain: a selected review of preclinical studies. Annals of Palliative Medicine, 2017, 6, S209-S214.	1.2	22
56	Symptom correlates of dyspnea in advanced cancer patients using the Edmonton Symptom Assessment System. Supportive Care in Cancer, 2020, 28, 87-98.	2.2	22
57	Enteral and parenteral nutrition in cancer patients, a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis. Supportive Care in Cancer, 2020, 28, 979-1010.	2.2	22
58	Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines. Supportive Care in Cancer, 2019, 27, 783-791.	2.2	21
59	The Canadian Frailty Priority Setting Partnership: Research Priorities for Older Adults Living with Frailty. Canadian Geriatrics Journal, 2019, 22, 23-33.	1.2	21
60	Could time of whole brain radiotherapy delivery impact overall survival in patients with multiple brain metastases?. Annals of Palliative Medicine, 2016, 5, 267-279.	1.2	20
61	Magnetic Resonance–Guided High-Intensity-Focused Ultrasound for Palliation of Painful Skeletal Metastases: A Pilot Study. Technology in Cancer Research and Treatment, 2017, 16, 570-576.	1.9	20
62	An update in symptom clusters using the Edmonton Symptom Assessment System in a palliative radiotherapy clinic. Supportive Care in Cancer, 2017, 25, 3321-3327.	2,2	19
63	Symptoms Predictive of Overall Quality of Life Using the Edmonton Symptom Assessment Scale in Breast Cancer Patients Receiving Radiotherapy. Clinical Breast Cancer, 2019, 19, 405-410.	2.4	19
64	Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?. Canadian Family Physician, 2007, 53, 1177-84.	0.4	19
65	High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate. European Journal of Clinical Pharmacology, 2016, 72, 1391-1399.	1.9	18
66	Does gender affect self-perceived pain in cancer patients? â€"A meta-analysis. Annals of Palliative Medicine, 2017, 6, S177-S184.	1.2	18
67	Factors Associated With Opioid Use in Long-term Cancer Survivors. Journal of Pain and Symptom Management, 2019, 58, 100-107.e2.	1.2	18
68	Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Supportive Care in Cancer, 2021, 29, 3439-3459.	2.2	18
69	Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist, 2019, 24, 537-548.	3.7	17
70	Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy. Annals of Palliative Medicine, 2015, 4, 70-7.	1.2	17
71	Prophylaxis of radiation-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. Annals of Palliative Medicine, 2017, 6, 104-117.	1.2	16
72	A prospective study of docetaxel-associated pain syndrome. Supportive Care in Cancer, 2018, 26, 203-211.	2.2	16

#	Article	IF	CITATIONS
73	Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. Annals of Palliative Medicine, 2018, 7, 221-233.	1.2	16
74	Aprepitant and Granisetron for the Prophylaxis of Radiotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Radiotherapy for Bone Metastases: A Prospective Pilot Study. Current Oncology, 2014, 21, 760-767.	2.2	15
75	Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study. Annals of Palliative Medicine, 2016, 5, 172-178.	1.2	15
76	A novel prospective descriptive analysis of nausea and vomiting among patients receiving gastrointestinal radiation therapy. Supportive Care in Cancer, 2016, 24, 1545-1561.	2.2	15
77	Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study. CMAJ Open, 2020, 8, E191-E198.	2.4	15
78	Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy. Quality of Life Research, 2016, 25, 2535-2541.	3.1	14
79	Timing and duration of 5-HT3 receptor antagonist therapy for the prophylaxis of radiotherapy-induced nausea and vomiting: a systematic review of randomized and non-randomized studies. Journal of Radiation Oncology, 2013, 2, 271-284.	0.7	13
80	Eliciting patients' preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment. Supportive Care in Cancer, 2013, 21, 245-251.	2.2	13
81	Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Supportive Care in Cancer, 2018, 26, 2519-2549.	2.2	13
82	The incidence of neuropathic pain in bone metastases patients referred for palliative radiotherapy. Radiotherapy and Oncology, 2016, 118, 557-561.	0.6	12
83	A prospective study validating the EORTC QLQ-BM22 bone metastases module in patients with painful bone metastases undergoing palliative radiotherapy. Radiotherapy and Oncology, 2016, 119, 208-212.	0.6	12
84	A review of the Rapid Response Radiotherapy Program in patients with advanced cancer referred for palliative radiotherapy over two decades. Supportive Care in Cancer, 2019, 27, 2131-2134.	2.2	12
85	Self-reported pain in breast cancer patients receiving adjuvant radiotherapy. Supportive Care in Cancer, 2021, 29, 155-167.	2.2	12
86	Effect of re-irradiation for painful bone metastases on urinary markers of osteoclast activity (NCIC) Tj ETQq0 0 C	rgBT/Ove	erlock 10 Tf 50
87	Genetic biomarkers associated with pain flare and dexamethasone response following palliative radiotherapy in patients with painful bone metastases. Annals of Palliative Medicine, 2017, 6, S240-S247.	1.2	11
88	Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron. Therapeutics and Clinical Risk Management, 2015, 11, 713.	2.0	10
89	Symptom clusters of gastrointestinal cancer patients undergoing radiotherapy using the Functional Living Index—Emesis (FLIE) quality-of-life tool. Supportive Care in Cancer, 2015, 23, 2589-2598.	2.2	10
90	Impact of radiation-induced nausea and vomiting on quality of life. Supportive Care in Cancer, 2018, 26, 3959-3966.	2.2	10

#	Article	IF	CITATIONS
91	Gender differences in pain and patient reported outcomes: a secondary analysis of the NCIC CTG SC. 23 randomized trial. Annals of Palliative Medicine, 2017, 6, S185-S194.	1.2	10
92	Dexamethasone toxicity and quality of life in patients with brain metastases following palliative whole-brain radiotherapy. Journal of Radiation Oncology, 2013, 2, 435-443.	0.7	9
93	Comparison of Opioid Prescribing Among Cancer and Noncancer Patients Aged 18–64: Analysis Using Administrative Data. Journal of Pain and Symptom Management, 2018, 56, 72-79.	1.2	9
94	Should dexamethasone be standard in the prophylaxis of pain flare after palliative radiotherapy for bone metastases?â€"a debate. Annals of Palliative Medicine, 2018, 7, 279-283.	1.2	9
95	A pilot study with palonosetron in the prophylaxis of radiation-induced nausea and vomiting. Annals of Palliative Medicine, 2018, 7, 211-220.	1.2	9
96	Predictive biomarkers of chemotherapy-induced peripheral neuropathy: a review. Biomarkers in Medicine, 2018, 12, 907-916.	1.4	9
97	Re-analysis of symptom clusters in advanced cancer patients attending a palliative outpatient radiotherapy clinic. Annals of Palliative Medicine, 2019, 8, 140-149.	1.2	9
98	Pain descriptors of taxane acute pain syndrome (TAPS) in breast cancer patientsâ€"a prospective clinical study. Supportive Care in Cancer, 2020, 28, 589-598.	2.2	9
99	The Generation of Two Specific Cancer Costing Algorithms Using Ontario Administrative Databases. Current Oncology, 2019, 26, 682-692.	2.2	9
100	Baseline Blood Work Before Initiation of Chemotherapy: What Is Safe in the Real World?. Journal of Oncology Practice, 2013, 9, e182-e185.	2.5	8
101	Ondansetron Rapidly Dissolving Film for the Prophylactic Treatment of Radiation-Induced Nausea and Vomiting—A Pilot Study. Current Oncology, 2015, 22, 199-210.	2.2	8
102	An Overview of Radiation-Induced Nausea and Vomiting. Journal of Medical Imaging and Radiation Sciences, 2016, 47, S29-S38.	0.3	8
103	Patient Reported Outcomes After Radiation Therapy for Bone Metastases as a Function of Age: A Secondary Analysis of the NCIC CTG SC—Twenty-Three Randomized Trial. American Journal of Hospice and Palliative Medicine, 2018, 35, 718-723.	1.4	8
104	Symptom clusters using the EORTC QLQ-C15-PAL in palliative radiotherapy. Annals of Palliative Medicine, 2018, 7, 192-204.	1.2	8
105	Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients. Supportive Care in Cancer, 2021, 29, 4269-4275.	2.2	8
106	Olanzapine 5Âmg vs 10Âmg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. Supportive Care in Cancer, 2022, 30, 1015-1018.	2.2	8
107	Incorporation of life expectancy estimates in the treatment of palliative care patients receiving radiotherapy: treatment approaches in light of incomplete prognostic models. Annals of Palliative Medicine, 2015, 4, 162-8.	1.2	8
108	Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients. Supportive Care in Cancer, 2004, 12, 844-851.	2,2	7

#	Article	IF	CITATIONS
109	Should Bone Metastases Causing Neuropathic Pain be Treated with Single-dose Radiotherapy?. Clinical Oncology, 2011, 23, 482-484.	1.4	7
110	Are we better a decade later in the accuracy of survival prediction by palliative radiation oncologists?. Annals of Palliative Medicine, 2019, 8, 150-158.	1.2	7
111	Latest advances in the management of radiation-induced pain flare, nausea and vomiting. Annals of Palliative Medicine, 2016, 5, 50-7.	1.2	7
112	Radioimmunodetection of Colorectal Cancer Metastases with sup 131 / sup I-Labeled Monoclonal Antibody B72.3: A Pilot Study to Determine Efficacy of Detection and Pharmacokinetics. Cancer Investigation, 1993, 11, 129-134.	1.3	6
113	Doctor, What Are My Options? a Prospective Cohort Study of an Individualized Care Plan for Patients with Gastrointestinal Cancer. Current Oncology, 2015, 22, 171-177.	2.2	6
114	Classification of painful bone metastases as mild, moderate, or severe using both EORTC QLQ-C15-PAL and EORTC QLQ-BM22. Supportive Care in Cancer, 2016, 24, 4871-4878.	2.2	6
115	Which pain intensity scale from the Brief Pain Inventory correlates most highly with functional interference scores in patients experiencing taxane-induced arthralgia and myalgia?. Supportive Care in Cancer, 2016, 24, 2979-88.	2.2	6
116	A systematic review of methodologies, endpoints, and outcome measures in randomized trials of radiation therapy-induced nausea and vomiting. Supportive Care in Cancer, 2017, 25, 2019-2033.	2.2	6
117	Development and validation of a patient-reported questionnaire assessing systemic therapy induced diarrhea in oncology patients. Health and Quality of Life Outcomes, 2017, 15, 249.	2.4	6
118	To prep or not to prep - that is the question: A randomized trial on the use of antiflatulent medication as part of bowel preparation for patients having image guided external beam radiation therapy to the prostate. Practical Radiation Oncology, 2018, 8, 116-122.	2.1	6
119	Efficacy and safety of 1-day versus 3-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. Journal of Hospital Management and Health Policy, 2018, 2, 25-25.	0.4	6
120	Patient-reported fatigue in breast cancer patients receiving radiation therapy. Breast, 2019, 47, 10-15.	2.2	6
121	Potential Limitations of Bioluminescent Xenograft Mouse Models: A Systematic Review. Journal of Pharmacy and Pharmaceutical Sciences, 2020, 23, 177-199.	2.1	6
122	Genetic biomarkers associated with changes in quality of life and pain following palliative radiotherapy in patients with bone metastases. Annals of Palliative Medicine, 2017, 6, S248-S256.	1.2	6
123	Compatibility of dexamethasone sodium phosphate with hydromorphone hydrochloride or diphenhydramine hydrochloride. American Journal of Health-System Pharmacy, 1991, 48, 2161-2166.	1.0	5
124	International radiation oncology trainee decision making in the management of radiotherapy-induced nausea and vomiting. Supportive Care in Cancer, 2013, 21, 2041-2048.	2.2	5
125	Does Pregabalin Still Have a Role in Treating Cancer-Induced Bone Pain?. Journal of Clinical Oncology, 2016, 34, 524-526.	1.6	5
126	Evolution of antiemetic studies for radiation-induced nausea and vomiting within an outpatient palliative radiotherapy clinic. Supportive Care in Cancer, 2019, 27, 3245-3252.	2.2	5

#	Article	IF	Citations
127	Operationalizing Outpatient Palliative Care Referral Criteria in Lung Cancer Patients: A Population-Based Cohort Study Using Health Administrative Data. Journal of Palliative Medicine, 2020, 23, 670-677.	1.1	5
128	Efficacy of granisetron and aprepitant in a patient who failed ondansetron in the prophylaxis of radiation induced nausea and vomiting: a case report. Annals of Palliative Medicine, 2015, 4, 32-4.	1.2	5
129	Re-irradiation for painful bone metastases: evidence-based approach. Annals of Palliative Medicine, 2015, 4, 214-9.	1.2	5
130	Fatigue scores in patients receiving palliative radiotherapy for painful bone metastases. Supportive Care in Cancer, 2015, 23, 2097-2103.	2.2	4
131	Use of urinary markers in cancer setting: A literature review. Journal of Bone Oncology, 2015, 4, 18-23.	2.4	4
132	Urinary cytokines/chemokines after magnetic resonance-guided high intensity focused ultrasound for palliative treatment of painful bone metastases. Annals of Palliative Medicine, 2017, 6, 36-54.	1.2	4
133	Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation. Annals of Palliative Medicine, 2017, 6, S13-S20.	1.2	4
134	Development of a process map for the delivery of virtual clinical pharmacy services at Odette Cancer Centre during the COVID-19 pandemic. Journal of Oncology Pharmacy Practice, 2021, 27, 650-657.	0.9	4
135	Urinary cytokines/chemokines pattern in patients with painful bone metastases undergoing external beam radiotherapy experiencing pain flare. Annals of Palliative Medicine, 2016, 5, 107-115.	1.2	4
136	Drug extravasation along the route of a peritoneal catheter during intraperitoneal chemotherapy. Cancer, 1987, 60, 1731-1733.	4.1	3
137	Has Province-Wide Symptom Screening Changed Opioid Prescribing Rates in Older Patients With Cancer?. Journal of Oncology Practice, 2017, 13, e927-e934.	2.5	3
138	Symptom clusters using the Brief Pain Inventory in patients with breast cancer. Annals of Palliative Medicine, 2017, 6, S170-S176.	1.2	3
139	A prospective cohort study of patient-reported vomiting, retching, nausea and antiemetic use during neoadjuvant long-course radiation therapy and concurrent 5-fluorouracil-based chemotherapy for rectal adenocarcinoma. Clinical and Translational Radiation Oncology, 2018, 10, 42-46.	1.7	3
140	Management of radiation-induced nausea and vomiting with palonosetron in patients with pre-existing emesis: a pilot study. Annals of Palliative Medicine, 2018, 7, 385-392.	1.2	3
141	A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga \hat{A}°) to the reference biologic (Neulasta \hat{A}°). Journal of Oncology Pharmacy Practice, 2022, 28, 5-16.	0.9	3
142	Doctor, what are my options? A prospective cohort study of an individualized care plan for patients with gastrointestinal cancer Journal of Clinical Oncology, 2012, 30, 12-12.	1.6	3
143	Description and Disposition of Patients With Cancer Accessing a Novel, Pharmacist-Led Cannabis Consultation Service. JCO Oncology Practice, 0, , .	2.9	3
144	Phase I and pharmacokinetic study of high volume intraperitoneal aclacinomycin? A (Aclarubicin). Investigational New Drugs, 1987, 5, 171-6.	2.6	2

#	Article	IF	CITATIONS
145	Can Patient Risk Factors Outperform Antiemetic Guidelines?. JAMA Oncology, 2016, 2, 232.	7.1	2
146	Adverse Health Outcomes Associated with Postdiagnosis Smoking in Prostate Cancer Patients: A Literature Review. Journal of Medical Imaging and Radiation Sciences, 2017, 48, 103-110.	0.3	2
147	Genetic biomarkers associated with response to palliative radiotherapy in patients with painful bone metastases. Annals of Palliative Medicine, 2017, 6, S233-S239.	1.2	2
148	Anticipatory nausea: current landscape and future directions. Annals of Palliative Medicine, 2017, 6, 1-2.	1.2	2
149	Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis. Critical Reviews in Oncology/Hematology, 2019, 142, 164-186.	4.4	2
150	Patient-Reported Pain in Patients with Breast Cancer Who Receive Radiotherapy. Pain Management Nursing, 2021, 22, 402-407.	0.9	2
151	Characterizing the risk of drug-drug interactions in patients receiving enzalutamide for castration-resistant prostate cancer Journal of Clinical Oncology, 2015, 33, 261-261.	1.6	2
152	Comparison of mortality between nosocomial and community-acquired febrile neutropenia patients treated initially with cefazolin plus tobramycin: retrospective chart review. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 1141-1150.	2.9	1
153	Validation of the long-term quality of life breast cancer scale (LTQOL-BC) by health care professionals. Supportive Care in Cancer, 2015, 23, 1629-1635.	2,2	1
154	Quality of life with Brain Symptom and Impact Questionnaire in patients with brain metastases. Annals of Palliative Medicine, 2016, 5, 179-189.	1.2	1
155	Evaluation of the 3-day recall period for the Functional Life Index-Emesis (FLIE). Annals of Palliative Medicine, 2018, 7, 393-403.	1.2	1
156	Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?. Annals of Palliative Medicine, 2021, 10, 2540-2547.	1.2	1
157	Comprehensiveness of Quality of Life Instruments in Capturing Concerns Related to Chemotherapy-Induced Neutropenia. Blood, 2008, 112, 1311-1311.	1.4	1
158	Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis against Febrile Neutropenia in Lymphoma Patients Receiving R-CHOP Chemotherapy Blood, 2009, 114, 2475-2475.	1.4	1
159	Use of performance data to drive process change and improve patient wait time for chemotherapy treatment Journal of Clinical Oncology, 2012, 30, 223-223.	1.6	1
160	P73. Pain flare following radiotherapy for painful bone metastases: A joint effort of three cancer centres to determine the incidence. Cancer Treatment Reviews, 2008, 34, 34-35.	7.7	0
161	B06-C Improved Pain and Quality of Life as Early as Day 10 Following Radiotherapy for Painful Bone Metastases: A Secondary Analysis of the NCIC CTG SC.23 Randomized Trial. Journal of Pain and Symptom Management, 2016, 52, e17-e18.	1.2	0
162	Has pain management improved over the last decade in the Rapid Response Radiotherapy Program?. Current Opinion in Supportive and Palliative Care, 2016, 10, 3-4.	1.3	0

#	Article	IF	CITATIONS
163	Prophylactic dexamethasone for radiation-induced bone-pain flare – Authors' reply. Lancet Oncology, The, 2016, 17, e40-e41.	10.7	0
164	Do patients receiving pelvic radiation and anti-emetics experience diarrhea and/or constipation?. Annals of Palliative Medicine, 2017, 6, S71-S76.	1.2	0
165	Symptom Control. , 2018, , 417-417.		0
166	Deriving Health Utility Values From a Health-Related Quality of Life Instrument in Non-Hodgkin Lymphoma Patients. Blood, 2011, 118, 2065-2065.	1.4	0
167	Use of zoledronic acid therapy–associated severe hypophosphatemia to identify poor-prognosis patients with metastatic castration-resistant prostate cancer Journal of Clinical Oncology, 2012, 30, 58-58.	1.6	0
168	Severe zoledronic acid (ZOL)-associated hypophosphatemia and prognosis in patients with castration-resistant prostate cancer (CRPC) Journal of Clinical Oncology, 2012, 30, e15180-e15180.	1.6	0
169	Assessing alternative dosing strategies for granulocyte-colony stimulating factor (G-CSF) use with FOLFOX6 therapy for treatment of colorectal cancer in a prospective cohort Journal of Clinical Oncology, 2015, 33, 771-771.	1.6	0
170	Drug-drug interactions in patients with castration-resistant prostate cancer undergoing abiraterone therapy: Characterizing the scale of the problem Journal of Clinical Oncology, 2015, 33, 269-269.	1.6	0
171	Time trends in opioid use in cancer and noncancer patients: Observations from administrative data Journal of Clinical Oncology, 2016, 34, 298-298.	1.6	0
172	Opioid use in long term cancer survivors Journal of Clinical Oncology, 2018, 36, 6520-6520.	1.6	0
173	Impact of treatment on patient-reported pain and fatigue in early breast cancer patients receiving adjuvant radiotherapy Journal of Clinical Oncology, 2019, 37, e12019-e12019.	1.6	0
174	Developing a standardized approach to cancer medication-related infusion reaction prevention and management in Ontario Journal of Clinical Oncology, 2019, 37, 255-255.	1.6	0
175	From guidelines to practice: Patient-focused and evidence-informed update of antiemetic recommendations in Ontario Journal of Clinical Oncology, 2019, 37, 39-39.	1.6	0
176	The Real-World Experience of the Biosimilar (Grastofil®) to the Reference Biologic (Neupogen®) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study. Current Oncology, 2022, 29, 1349-1369.	2.2	0